Cargando…
Final 4-year results of the RAINBOW real-world study: intravitreal aflibercept dosing regimens in France in treatment-naïve patients with neovascular age-related macular degeneration
PURPOSE: The purpose of this study is to evaluate real-world treatment outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept (IVT-AFL) in routine clinical practice in France. METHODS: RAINBOW (NCT02279537) was an ambispective, observation...
Autores principales: | Cohen, Salomon-Yves, Dominguez, Marcel, Coscas, Florence, Faure, Céline, Baillif, Stéphanie, Oubraham, Hassiba, Kodjikian, Laurent, Weber, Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049954/ https://www.ncbi.nlm.nih.gov/pubmed/36399178 http://dx.doi.org/10.1007/s00417-022-05900-6 |
Ejemplares similares
-
Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
por: Weber, Michel, et al.
Publicado: (2020) -
Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration in routine clinical practice in France: results from the RAINBOW study
por: Weber, Michel, et al.
Publicado: (2020) -
Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept
por: Parvin, Parmis, et al.
Publicado: (2017) -
Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014) -
Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration—12-month post hoc analysis of the PERSEUS real-world evidence study
por: Wachtlin, Joachim, et al.
Publicado: (2020)